in tumor therapy against B16-OVA-derived melanomas, whereas this function was lost in Batf3 -/-mice. These experiments show that cross-priming of tumor antigens by Flt3L-and Batf3-dependent DCs is crucial to the efficacy of immunostimulatory mAbs and represents a very attractive point of intervention to enhance their clinical antitumor effects.
Statement of significance
Immunotherapy with immunostimulatory monoclonal antibodies (mAbs) is currently achieving durable clinical responses in different types of cancer. We show that crosspriming of tumor antigens by Batf3-dependent dendritic cells is a key limiting factor that can be exploited to enhance the antitumor efficacy of anti-PD-1 and anti-CD137 immunostimulatory mAbs.
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INTRODUCTION
Tumor cells are antigenic as a result of abundant mutated sequences in their exomes (1) .
However, they are poorly immunogenic to prime cytotoxic T lymphocyte (CTL) responses because antigen presentation takes place in the absence of appropriate costimulation, and in a strongly immunosuppressive environment (2) . The immune response to cell-associated antigens requires the interplay of specialized and professional antigen presenting cells called dendritic cells (DCs) . Among the variety of DC subsets, certain DCs excel at redirecting cell-associated phagocytosed proteins to the MHC class I antigen presentation pathway (3), a process termed cross-presentation, or cross-priming if it results in CD8 T cell activation. There is evidence that tumor antigens are efficiently cross-presented in vivo (4) .
Two DC subsets have been identified in mice as the most efficient at crosspriming in vivo: lymphoid-tissue resident CD11c + CD8 + Clec9a/DNGR-1 + XCR1 + DCs and migratory CD11c + CD103 + Clec9a/DNGR-1 + XCR1 + DCs (5) . Differentiation of both DC subsets shows an absolute requirement for Flt3L, and is largely affected by the absence of Batf3 (6) . Notably, the absence of Batf3 not only impairs numbers, but also functional responses in the remaining CD11c + Clec9a/DNGR1 + XCR1 + DCs, such as cell-associated cross-presentation or IL-12 production (7, 8) . Notably, Batf3 -/-mice show impaired immunity against syngeneic immunogenic fibrosarcomas (6) and regulate T cell infiltration in models of melanoma (9) . However, other Batf3-independent DC subsets mediate the immune system-dependent antitumor activity of anthracyclines (10) and mediate tumor rejection under activating conditions in Batf3-deficient mice (11) . Recent reports further support an important role for intratumoral Batf3-dependent CD103 + DCs in priming a CTL response through IL-12 production 6 (12, 13). In humans, an equivalent Batf3-dependent DC subset characterized by expression of CD11c, CD141, Clec9a/DNGR-1 and XCR1 has been identified in peripheral blood and lymphoid organs (14) .
Immunotherapy of cancer is currently being revolutionized by the use of immunomodulatory monoclonal antibodies (mAbs). Interaction of PD-1 (CD279), on activated and exhausted lymphocytes, with its ligands (PD-L1 or PD-L2, expressed on antigen-presenting DCs and tumor cells) downmodulates T cell signaling (15, 16) .
Interference with these interactions using mAbs to PD-1 or PD-L1 has proved effective in cancer patients with metastatic melanoma, renal cell carcinoma, non-small lung cancer, bladder cancer, head and neck cancer, and other malignancies (17) . In addition, stimulation of the costimulatory receptor on activated T lymphocytes CD137 (4-1BB) (18) results in complete tumor rejection in some transplantable tumor models (19) .
These promising findings have led to the clinical development of two anti-CD137 agents mainly for refractory lymphoma (BMS-663513/Urelumab and PF-05082566; NCT01775631, NCT02253992, NCT01307267).
The anti-PD-1 and anti-CD137 mAbs both induce tumor rejection by synergizing with vaccines (20) , indicating that their function relies on a preexisting suboptimal CTL immune response that, if boosted, results in synergistic effects (1) . Herein, we find an absolute need for Batf3-dependent DCs in cross-priming of tumor antigens to CTLs that subsequently upregulate PD-1 and CD137. This antitumor response can thus be manipulated with exogenous immunostimulatory mAbs. In consequence, expansion and activation of Batf3-dependent DCs concomitant with anti-CD137 mAb or anti-PD-1 treatment results in a suitable combined antitumor therapy.
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RESULTS
Ineffective antitumor therapy with immunomodulatory mAbs in Batf3 -/-mice
The absence of Batf3 affects the ontogeny and function of CD8 + DCs in lymphoid organs and CD103 + DCs in the periphery, impairing cell-associated cross-presentation and the ability to produce IL-12 in response to infectious challenge. The antitumor effects of immunostimulatory anti-PD-1 and anti-CD137 mAbs are contingent on an already present baseline immune response, which is rescued and amplified by treatment.
Based on the proposed role for Batf3-dependent DCs in immune-surveillance (6), we hypothesized that the preexisting immune response rescued by the immunostimulatory mAbs might be mediated by Batf3-dependent cross-priming. Grafted MC38-derived tumors were lethal in C57Bl/6 WT and Batf3-deficient mice, with slightly faster progression in Batf3 -/-mice (Fig. 1A) . In WT mice, tumor growth was delayed or curtailed by a course of treatment with anti-PD-1 or anti-CD137 mAbs, starting on day 4 after tumor cell inoculation. Combination treatment with both mAbs had a synergistic effect on their antitumor action ( Fig. 1A and 1B) , as previously reported in in other tumor models (21) . The antitumor efficacy of anti-CD137 and anti-PD-1 mAbs, used alone or in combination, was abolished in Batf3 -/-mice ( Fig. 1A and 1B (Fig. 1C) . In stark contrast, no therapeutic effect was seen in identically treated Batf3 -/-mice (Fig. 1C) . Administration of IL-12 is thus unable to compensate the loss of a key function of Batf3-dependent DCs in the synergy with immunostimulatory anti-CD137 mAb.
Impaired ability of Batf3 -/-DCs to cross-prime CTLs against tumor antigens
To investigate the possible involvement of deficient cross-presentation in the non- We further analyzed the response against gp70, a well-described endogenous antigen in MC38 colon cancer cells (23) . Notably, CD8 + TILs specific for gp70 were increased in a Batf3-dependent fashion upon anti-CD137 and anti-PD-1 mAb treatment, as detected by pentamer staining ( Figure 2H) . A similar analysis of the response to the Adpgk mutated neoantigen (24) showed some positive responses in WT but not Batf3-deficient mice ( Supplementary Fig. S2 , A and B).
Priming of CD137 + PD1 + antigen-specific TILs by activated Batf3-dependent DCs
We hypothesized that expansion and activation of Batf3-dependent DCs with sFlt3L
and the TLR3 adjuvant poly-ICLC would synergize with immunostimulatory mAbs to enhance priming of tumor-specific CD8 + T cells. To extend our results to an alternative tumor model, we used B16-OVA melanoma cells grafted subcutaneously.
Hydrodynamic injection of a plasmid expressing sFlt3L markedly promoted the expansion of cross-presenting DCs ( Supplementary Fig. S3A ). Intratumoral administration of poly-ICLC increased some activation markers including CD40 and PD-L1 in DCs from the in spleen, tumor and tumor-draining LN, particularly in the TLR3-expressing CD103 + DCs ( Supplementary Fig. S3B-S3D ). Immunity to B16-OVA was estimated from the number of TILs detected by OVA-MHC-tetramer staining, and was almost undetectable in control mice treated with empty vector and intratumoral saline buffer (Fig. 3A) . Systemic hydrodynamic injection of sFlt3L combined with intratumoral injection of poly-ICLC raised a specific antitumor CTL response, and this induction was blocked in Batf3 -/-mice (Fig. 3A) . These events were paralleled by an increased frequency of CD137 + CD8 + T cells in WT mice treated with sFlt3L and poly-ICLC, and the impairment of this effect in Batf3 -/-mice (Fig. 3B) . Notably, antigenspecific TILs showed higher surface expression of PD-1 and CD137 compared with the bulk of CD8 infiltrating T cells (Fig. 3C) . These results show that expansion and activation of Batf3-dependent DCs increases the frequency of primed CD8 + T cells that upregulate markers of activation and exhaustion and are sensitive to immunostimulatory mAb treatment because of the expression of the targets for such agents.
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Batf3-dependent DC activation enhances antitumor ability of immunomodulatory mAbs
We next sought to establish how Flt3L-and poly-ICLC-enhanced priming of CD8 + T cells affects the antitumor efficacy of anti-CD137 and anti-PD-1 mAbs. For this analysis we used the B16-OVA model, which in our hands responds weakly or not at all to anti-PD-1 or anti-CD137 mAb treatment (Fig. 4, A Each addition to our knowledge in this area of tumor antigen cross-priming has the potential to provide predictive biomarkers for the efficacy of immunostimulatory mAbs, since cross-priming against tumor neo-antigens seems to be a key determinant of the variable efficacy of these treatments in mice and humans (1, 12, 28) . Moreover, more effective vaccines could be prepared by immune sorting or targeting these cross-priming DC populations or their differentiation in culture from precursors (29) .
Overall, our results raise important pointers for improving therapy with immunostimulatory mAbs. The cross-priming function of DCs is essential for the therapeutic effect of immunostimulatory mAbs, but the baseline CTL-priming function is suboptimal. These observations suggest the potential to devise exogenous or in situ tumor vaccination therapies to enhance cross-priming of tumor antigens and thereby increase the efficacy of immunostimulatory mAbs.
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MATERIALS AND METHODS
Mice
Mice were bred at the CNIC and the CIMA in specific pathogen-free conditions. Batf3 Melief (Leiden University Medical Center, Netherlands) in November 2013 and were not further verified. All cell lines were cultured at 37ºC with 5% CO 2 . Isolated lymph nodes (LN) were incubated in collagenase/DNase for 15 minutes at 37ºC, followed by mechanical disaggregation using frosted slides. Single cell suspensions were then stained for flow cytometry.
Flow cytometry
Acquisition was performed using a FACS Canto II flow cytometer (BD Biosciences).
The antibodies used included FITC-conjugated αPD-1 (29F. 
In vivo tumor experiments
Cultured tumor cells were trypsinized before reaching confluence and suspended in phosphate buffered saline (PBS). Unless specified otherwise, 5 x 10 5 cells in 50 µl PBS were used for inoculation. Cells were injected subcutaneously (s.c.) using 29G syringes into the shaved right flank of 8-12 week-old C57Bl/6 Batf3 -/-and WT mice. Tumor size was measured twice weekly and calculated as the product of orthogonal diameters.
Anti-CD137 (1D8) antibody was produced as described (19) . Anti-PD-1 (RMP1-14)
antibody was purchased from BioXcell. Antibodies ( 
Statistical analysis
Tumor growth data were analyzed with Prism software (GraphPad Software, Inc.). ), where t represents time, A the maximum size reached by the tumor and B its growth rate. Treatments were compared using the extra sum-of-squares F test. Tumor survival was compared with log-rank (Mantel-Cox) tests. All other analyses among groups were performed as described in figure legends.
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